Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
04 Febrero 2021 - 6:10AM
Business Wire
- Acceleron expects to report approximately
$23.0 million in royalty revenue for Q4 2020 from approximately
$115 million in net sales of REBLOZYL® (luspatercept-aamt) as
reported by Bristol Myers Squibb -
- Acceleron expects to report approximately
$54.8 million in royalty revenue for full year 2020 from
approximately $274 million in net sales of REBLOZYL as reported by
Bristol Myers Squibb -
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company
dedicated to the discovery, development, and commercialization of
TGF-beta superfamily therapeutics to treat serious and rare
diseases, today announced net sales of REBLOZYL®
(luspatercept-aamt) as reported by its global collaborator, Bristol
Myers Squibb, were approximately $115 million for the fourth
quarter and approximately $274 million for the full year ended
December 31, 2020.
Acceleron expects to report royalty revenue of approximately
$23.0 million from net sales of REBLOZYL in the fourth quarter
ended December 31, 2020. This compares with approximately $19.3
million in royalty revenue from approximately $96 million of net
sales of REBLOZYL for the third quarter ended September 30, 2020.
For the full year 2020, Acceleron expects to report royalty revenue
of approximately $54.8 million.
The preliminary unaudited revenue estimates for the quarter and
full year ended December 31, 2020 included in this release are the
responsibility of management and are subject to the completion of
the Company’s customary quarter and year-end financial closing
procedures, including management’s review and finalization, as well
as audit procedures by the Company’s independent registered public
accounting firm, which have not yet been completed. During the
course of the Company’s review process, items may be identified
that would require it to make adjustments, which could result in
material changes to the Company’s preliminary unaudited estimated
financial results. Consequently, these revenue estimates should not
be viewed as substitutes for the Company’s earnings release and
Annual Report on Form 10-K.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and
commercialization efforts in pulmonary and hematologic diseases. In
pulmonary, Acceleron is developing sotatercept for the treatment of
pulmonary arterial hypertension (PAH), having reported positive
topline results of the PULSAR Phase 2 trial. The Company is
currently planning multiple Phase 3 trials with the potential to
support its long-term vision of establishing sotatercept as a
backbone therapy for patients with PAH at all stages of the
disease. Acceleron is also investigating the potential of its
early-stage pulmonary candidate, ACE-1334, which it plans to
advance into a Phase 1b/2 trial in systemic sclerosis-associated
interstitial lung disease (SSc-ILD) this year.
In hematology, REBLOZYL® (luspatercept-aamt) is the first and
only erythroid maturation agent approved in the United States,
Europe, and Canada for the treatment of anemia in certain blood
disorders. REBLOZYL is part of a global collaboration partnership
with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the
United States and are also developing luspatercept for the
treatment of anemia in patient populations of myelodysplastic
syndromes, beta-thalassemia, and myelofibrosis.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements about the
Company's financial results. The words "anticipate," "believe,"
"could," "estimate," "expect," "goal," "intend," "may," "plan,"
"potential," "project," "should," "target," "will," "would," and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to, that preclinical
testing of the Company's compounds and data from clinical trials
may not be predictive of the results or success of other clinical
trials, that regulatory approval of the Company’s compounds in one
indication or country may not be predictive of approval in another
indication or country, that the development of the Company’s
compounds may take longer and/or cost more than planned or
accelerate faster than currently expected, that the Company or its
collaboration partner, Bristol Myers Squibb (“BMS”), may be unable
to successfully complete the clinical development of the Company’s
compounds, that the Company or BMS may be delayed in initiating,
enrolling or completing any clinical trials, and that the Company’s
compounds may not receive regulatory approval or become
commercially successful products. These and other risks and
uncertainties are identified under the heading “Risk Factors”
included in the Company’s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q, and other filings that the Company
has made and may make with the SEC in the future.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions, and projections with respect to future events, and the
Company does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210204005601/en/
Acceleron Pharma Inc. Investors: Jamie Bernard, IRC,
617-301-9650 Associate Director, Investor Relations
Media: Matt Fearer, 617-301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024